Redefining Clinical Hyperprogression: The Incidence, Clinical Implications, and Risk Factors of Hyperprogression in Non-Small Cell Lung Cancer Treated with Immunotherapy

CONCLUSIONS: The incidence and risk factors of HPD varied with different definitions, but mHPD identified more cases with poor outcomes. This comprehensive approach may enhance the identification of at-risk patients and lead to a better understanding of HPD in lung cancer during immunotherapy.PMID:38644088 | DOI:10.1016/j.cllc.2024.03.001

Source: Clinical Lung Cancer - April 21, 2024 Category: Cancer & Oncology Authors: Trie Arni Djunadi Youjin Oh Jeeyeon Lee Jisang Yu Liam Il-Young Chung Yeunho Lee Leeseul Kim Timothy Hong Soowon Lee Zunairah Shah Joo Hee Park Sung Mi Yoon Young Kwang Chae Source Type: research